2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Choi Y, Dharia N, Jun T, Chang J, Royer-Joo S, Yau K, Assaf Z, Aimi J, Sivakumar S, Montesion M, Sacher A, LoRusso P, Desai J, Schutzman J, Shi Z, group A. Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors. Clinical Cancer Research 2024, 30: of1-of10. PMID: 38995268, PMCID: PMC11369623, DOI: 10.1158/1078-0432.ccr-24-0255.Peer-Reviewed Original ResearchConceptsKRAS G12C mutationTumor fractionSolid tumorsTumor typesG12C mutationOn-treatment time pointsNon-small cell lung cancerMutational heterogeneityAssociated with tumor typeProgression-free survivalPlasma samplesPhase 1 studyCell lung cancerCycle 1 dayAssociated with patient outcomesVariant allele frequencyAssociated with responseCtDNA levelsCtDNA profilingMetastatic sitesTruncal mutationsTumor DNATreatment responseLung cancerTumor tissues
2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
Kim T, Bedard P, LoRusso P, Gordon M, Bendell J, Oh D, Ahn M, Garralda E, D’Angelo S, Desai J, Hodi F, Wainberg Z, Delord J, Cassier P, Cervantes A, Gil-Martin M, Wu B, Patil N, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho B. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors. JAMA Oncology 2023, 9: 1574-1582. PMID: 37768658, PMCID: PMC10540058, DOI: 10.1001/jamaoncol.2023.3867.Peer-Reviewed Original ResearchConceptsObjective response rateAdvanced solid tumorsAdverse eventsPhase 1bAntitumor activityCancer cohortNon-small cell lung cancer (NSCLC) cohortFrequent treatment-related adverse eventsInvestigator-assessed objective response rateSolid tumorsCell lung cancer cohortTreatment-related adverse eventsMajority of AEsEnd pointClinical cutoff dateDose-escalation cohortsDose-expansion cohortsEsophageal cancer cohortPhase 2 dosePrior cancer therapyPrimary end pointSecondary end pointsHalf of patientsNew safety signalsAntitumor immune responseInterplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu C, Alimohamed S, Bashir B, Berg S, Bilen M, Bowles D, Castellano C, Desai A, Elkrief A, Eton O, Fecher L, Flora D, Galsky M, Gatti-Mays M, Gesenhues A, Glover M, Gopalakrishnan D, Gupta S, Halfdanarson T, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson D, Joshi M, Khan H, Khan S, Knox N, Koshkin V, Kulkarni A, Kwon D, Matar S, McKay R, Mishra S, Moria F, Nizam A, Nock N, Nonato T, Panasci J, Pomerantz L, Portuguese A, Provenzano D, Puc M, Rao Y, Rhodes T, Riely G, Ripp J, Rivera A, Ruiz-Garcia E, Schmidt A, Schoenfeld A, Schwartz G, Shah S, Shaya J, Subbiah S, Tachiki L, Tucker M, Valdez-Reyes M, Weissmann L, Wotman M, Wulff-Burchfield E, Xie Z, Yang Y, Thompson M, Shah D, Warner J, Shyr Y, Choueiri T, Wise-Draper T, Fromowitz A, Gandhi R, Gartrell B, Goel S, Halmos B, Makower D, O' Sullivan D, Ohri N, Portes M, Shapiro L, Shastri A, Sica R, Verma A, Butt O, Campian J, Fiala M, Henderson J, Monahan R, Stockerl-Goldstein K, Zhou A, Bitran J, Hallmeyer S, Mundt D, Pandravada S, Papaioannou P, Patel M, Streckfuss M, Tadesse E, Gatson N, Kundranda M, Lammers P, Loree J, Yu I, Bindal P, Lam B, Peters M, Piper-Vallillo A, Egan P, Farmakiotis D, Arvanitis P, Klein E, Olszewski A, Vieira K, Angevine A, Bar M, Del Prete S, Fiebach M, Gulati A, Hatton E, Houston K, Rose S, Steve Lo K, Stratton J, Weinstein P, Garcia J, Routy B, Hoyo-Ulloa I, Dawsey S, Lemmon C, Pennell N, Sharifi N, Painter C, Granada C, Hoppenot C, Li A, Bitterman D, Connors J, Demetri G, Florez (Duma) N, Freeman D, Giordano A, Morgans A, Nohria A, Saliby R, Tolaney S, Van Allen E, Xu W, Zon R, Halabi S, Zhang T, Dzimitrowicz H, Leighton J, Graber J, Grivas P, Hawley J, Loggers E, Lyman G, Lynch R, Nakasone E, Schweizer M, Vinayak S, Wagner M, Yeh A, Dansoa Y, Makary M, Manikowski J, Vadakara J, Yossef K, Beckerman J, Goyal S, Messing I, Rosenstein L, Steffes D, Alsamarai S, Clement J, Cosin J, Daher A, Dailey M, Elias R, Fein J, Hosmer W, Jayaraj A, Mather J, Menendez A, Nadkarni R, Serrano O, Yu P, Balanchivadze N, Gadgeel S, Accordino M, Bhutani D, Bodin B, Hershman D, Masson C, Alexander M, Mushtaq S, Reuben D, Bernicker E, Deeken J, Jeffords K, Shafer D, Cárdenas A, Cuervo Campos R, De-la-Rosa-Martinez D, Ramirez A, Vilar-Compte D, Gill D, Lewis M, Low C, Jones M, Mansoor A, Mashru S, Werner M, Cohen A, McWeeney S, Nemecek E, Williamson S, Peters S, Smith S, Lewis G, Zaren H, Akhtari M, Castillo D, Cortez K, Lau E, Nagaraj G, Park K, Reeves M, O'Connor T, Altman J, Gurley M, Mulcahy M, Wehbe F, Durbin E, Nelson H, Ramesh V, Sachs Z, Wilson G, Bardia A, Boland G, Gainor J, Peppercorn J, Reynolds K, Rosovsky R, Zubiri L, Bekaii-Saab T, Joyner M, Riaz I, Senefeld J, Shah S, Ayre S, Bonnen M, Mahadevan D, McKeown C, Mesa R, Ramirez A, Salazar M, Shah P, Wang C, Bouganim N, Papenburg J, Sabbah A, Tagalakis V, Vinh D, Nanchal R, Singh H, Bahadur N, Bao T, Belenkaya R, Nambiar P, O’Cearbhaill R, Papadopoulos E, Philip J, Robson M, Rosenberg J, Wilkins C, Tamimi R, Cerrone K, Dill J, Faller B, Alomar M, Chandrasekhar S, Hume E, Islam J, Ajmera A, Brouha S, Cabal A, Choi S, Hsiao A, Jiang J, Kligerman S, Park J, Razavi P, Reid E, Bhatt P, Mariano M, Thomson C, Glace M, Knoble J, Rink C, Zacks R, Blau S, Brown C, Cantrell A, Namburi S, Polimera H, Rovito M, Edwin N, Herz K, Kennecke H, Monfared A, Sautter R, Cronin T, Elshoury A, Fleissner B, Griffiths E, Hernandez-Ilizaliturri F, Jain P, Kariapper A, Levine E, Moffitt M, O'Connor T, Smith L, Wicher C, Zsiros E, Jabbour S, Misdary C, Shah M, Batist G, Cook E, Ferrario C, Lau S, Miller W, Rudski L, Santos Dutra M, Wilchesky M, Mahmood S, McNair C, Mico V, Dixon B, Kloecker G, Logan B, Mandapakala C, Cabebe E, Jha A, Khaki A, Nagpal S, Schapira L, Wu J, Whaley D, Lopes G, de Cardenas K, Russell K, Stith B, Taylor S, Klamerus J, Revankar S, Addison D, Chen J, Haynam M, Jhawar S, Karivedu V, Palmer J, Pillainayagam C, Stover D, Wall S, Williams N, Abbasi S, Annis S, Balmaceda N, Greenland S, Kasi A, Rock C, Luders M, Smits M, Weiss M, Chism D, Owenby S, Ang C, Doroshow D, Metzger M, Berenberg J, Uyehara C, Fazio A, Huber K, Lashley L, Sueyoshi M, Patel K, Riess J, Borno H, Small E, Zhang S, Andermann T, Jensen C, Rubinstein S, Wood W, Ahmad S, Brownfield L, Heilman H, Kharofa J, Latif T, Marcum M, Shaikh H, Sohal D, Abidi M, Geiger C, Markham M, Russ A, Saker H, Acoba J, Choi H, Rho Y, Feldman L, Gantt G, Hoskins K, Khan M, Liu L, Nguyen R, Pasquinelli M, Schwartz C, Venepalli N, Vikas P, Zakharia Y, Friese C, Boldt A, Gonzalez C, Su C, Su C, Yoon J, Bijjula R, Mavromatis B, Seletyn M, Wood B, Zaman Q, Kaklamani V, Beeghly A, Brown A, Charles L, Cheng A, Crispens M, Croessmann S, Davis E, Ding T, Duda S, Enriquez K, French B, Gillaspie E, Hausrath D, Hennessy C, Lewis J, Li X, Prescott L, Reid S, Saif S, Slosky D, Solorzano C, Sun T, Vega-Luna K, Wang L, Aboulafia D, Carducci T, Goldsmith K, Van Loon S, Topaloglu U, Moore J, Rice R, Cabalona W, Cyr S, Barrow McCollough B, Peddi P, Rosen L, Ravindranathan D, Hafez N, Herbst R, LoRusso P, Lustberg M, Masters T, Stratton C. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA Oncology 2023, 9: 128-134. PMID: 36326731, PMCID: PMC9634600, DOI: 10.1001/jamaoncol.2022.5357.Peer-Reviewed Original ResearchConceptsCOVID-19 severitySystemic anticancer therapyWorse COVID-19 severityCytokine stormBaseline immunosuppressionCohort studyAnticancer therapyCOVID-19Registry-based retrospective cohort studyIntensive care unit admissionCare unit admissionRetrospective cohort studyMulti-institutional registryLaboratory-confirmed infectionSevere clinical outcomesImmune system activationSARS-CoV-2Non-Hispanic whitesCOVID-19 diagnosisIO therapyPrevious cancerUnit admissionSecondary outcomesMedian agePrimary outcome
2022
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States
Hawley J, Sun T, Chism D, Duma N, Fu J, Gatson N, Mishra S, Nguyen R, Reid S, Serrano O, Singh S, Venepalli N, Bakouny Z, Bashir B, Bilen M, Caimi P, Choueiri T, Dawsey S, Fecher L, Flora D, Friese C, Glover M, Gonzalez C, Goyal S, Halfdanarson T, Hershman D, Khan H, Labaki C, Lewis M, McKay R, Messing I, Pennell N, Puc M, Ravindranathan D, Rhodes T, Rivera A, Roller J, Schwartz G, Shah S, Shaya J, Streckfuss M, Thompson M, Wulff-Burchfield E, Xie Z, Yu P, Warner J, Shah D, French B, Hwang C, Halmos B, Verma A, Gartrell B, Goel S, Ohri N, Sica R, Thakkar A, Stockerl-Goldstein K, Butt O, Campian J, Fiala M, Henderson J, Monahan R, Zhou A, Thompson M, Bohachek P, Mundt D, Streckfuss M, Tadesse E, Lammers P, Panagiotou O, Egan P, Farmakiotis D, Khan H, Olszewski A, Loaiza-Bonilla A, Del Prete S, Bar M, Gulati A, Steve Lo K, Rose S, Stratton J, Weinstein P, Caimi P, Barnholtz-Sloan J, Garcia J, Nakayama J, Gupta S, Pennell N, Ahluwalia M, Dawsey S, Lemmon C, Nizam A, Hoppenot C, Li A, Choueiri T, Bakouny Z, Bouchard G, Busser F, Connors J, Curran C, Demetri G, Giordano A, Kelleher K, Nohria A, Schmidt A, Shaw G, Van Allen E, Nuzzo P, Xu V, Zon R, Zhang T, Halabi S, Leighton J, Lyman G, Graber J, Grivas P, Khaki A, Loggers E, Lynch R, Nakasone E, Schweizer M, Tachiki L, Vinayak S, Wagner M, Yeh A, Gatson N, Goyal S, Huynh-Le M, Rosenstein L, Yu P, Clement J, Daher A, Dailey M, Elias R, Jayaraj A, Hsu E, Menendez A, Rathmann J, Serrano O, Hwang C, Gadgeel S, Singh S, Hawley J, Hershman D, Accordino M, Bhutani D, Schwartz G, Reuben D, Alexander M, Mushtaq S, Bernicker E, Deeken J, Shafer D, Lewis M, Rhodes T, Gill D, Low C, Mashru S, Mansoor A, Zaren H, Smith S, Nagaraj G, Akhtari M, Lau E, Reeves M, Berg S, Elms D, Morgans A, Wehbe F, Altman J, Gurley M, Mulcahy M, Durbin E, Kulkarni A, Nelson H, Sachs Z, Shah S, Rosovsky R, Reynolds K, Bardia A, Boland G, Gainor J, Zubiri L, Halfdanarson T, Bekaii-Saab T, Desai A, Xie Z, Mesa R, Bonnen M, Mahadevan D, Ramirez A, Salazar M, Shah D, Shah P, Faller B, McKay R, Ajmera A, Brouha S, Cabal A, Hsiao A, Kligerman S, Shaya J, Weissmann L, Jani C, Thomson C, Knoble J, Glace M, Rink C, Stauffer K, Zacks R, Blau S, Joshi M, Menon H, Rovito M, Griffiths E, Elshoury A, Jabbour S, Misdary C, Shah M, Bashir B, McNair C, Mahmood S, Mico V, Rivera A, Flora D, Logan B, Kloecker G, Mandapakala C, Shah S, Cabebe E, Glover M, Jha A, Schapira L, Wu J, Subbiah S, Lopes G, Revankar S, Stover D, Addison D, Chen J, Gatti-Mays M, Jhawar S, Karivedu V, Lustberg M, Palmer J, Wall S, Williams N, Wulff-Burchfield E, Kasi A, Edwin N, Smits M, Chism D, Owenby S, Doroshow D, Galsky M, Wotman M, Zhu H, Fu J, Fazio A, Sueyoshi M, Huber K, Riess J, Patel K, Rubinstein S, Wood W, Jensen C, Kumar V, Wise-Draper T, Ahmad S, Grover P, Gulati S, Kharofa J, Latif T, Marcum M, Park C, Shaikh H, Bowles D, Geiger C, Markham M, Bishnoi R, Russ A, Shah C, Acoba J, Rho Y, Feldman L, Hoskins K, Gantt G, Liu L, Khan M, Nguyen R, Pasquinelli M, Schwartz C, Venepalli N, Vikas P, Friese C, Fecher L, Mavromatis B, Bijjula R, Zaman Q, Warner J, Cheng A, Davis E, Duda S, Enriquez K, French B, Gillaspie E, Hennessy C, Hausrath D, Hsu C, Johnson D, Li X, Mishra S, Reid S, Rini B, Slosky D, Shyr Y, Solorzano C, Sun T, Tucker M, Vega-Luna K, Wang L, Kennecke H, Aboulafia D, Schroeder B, Puc M, Carducci T, Goldsmith K, Van Loon S, Topaloglu U, Alimohamed S, Rice R, Cabalona W, Pilar C, Peddi P, Rosen L, McCollough B, Bilen M, Ravindranathan D, Hafez N, Herbst R, LoRusso P, Masters T, Stratton C. Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Network Open 2022, 5: e2142046. PMID: 34982158, PMCID: PMC8728628, DOI: 10.1001/jamanetworkopen.2021.42046.Peer-Reviewed Original ResearchMeSH KeywordsAgedCause of DeathCensusesCOVID-19FemaleHealth FacilitiesHumansIntensive Care UnitsMaleMiddle AgedNeoplasmsOdds RatioPandemicsRegistriesRespiration, ArtificialRetrospective StudiesRisk FactorsRural PopulationSARS-CoV-2Severity of Illness IndexSocial VulnerabilitySpatial AnalysisUnited StatesUrban PopulationConceptsCOVID-19 outcomesRural-Urban Continuum CodesCohort studyLaboratory-confirmed SARS-CoV-2 infectionMortality rateUS census divisionsRegistry-based retrospective cohort studyIntensive care unit admissionRegistry-based cohort studySARS-CoV-2 infectionPatient-level risk factorsSecondary composite outcomeCare unit admissionRetrospective cohort studyCare of patientsCensus divisionsInvasive malignant neoplasmCOVID-19Significant differencesCOVID-19 diagnosisCause deathUnit admissionCause mortalityComposite outcomePatient characteristics
2021
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19
Schmidt A, Tucker M, Bakouny Z, Labaki C, Hsu C, Shyr Y, Armstrong A, Beer T, Bijjula R, Bilen M, Connell C, Dawsey S, Faller B, Gao X, Gartrell B, Gill D, Gulati S, Halabi S, Hwang C, Joshi M, Khaki A, Menon H, Morris M, Puc M, Russell K, Shah D, Shah N, Sharifi N, Shaya J, Schweizer M, Steinharter J, Wulff-Burchfield E, Xu W, Zhu J, Mishra S, Grivas P, Rini B, Warner J, Zhang T, Choueiri T, Gupta S, McKay R, Desai A, Cohen A, Olszewski A, Bardia A, Daher A, Brown A, Yeh A, Hsiao A, Cheng A, Zhou A, Beeghly-Fadiel A, Morgans A, Jha A, Menendez A, Fazio A, Nizam A, Ramirez A, Kulkarni A, Verma A, Elshoury A, Rivera A, Walden A, Piper-Vallillo A, Cook A, Li A, Cantrell A, Cabal A, Nohria A, Angevine A, Gulati A, Giordano A, Kasi A, Ajmera A, Elkrief A, Kariapper A, Loaiza-Bonilla A, Jayaraj A, Thakkar A, Russ A, Bashir B, Halmos B, Logan B, Wood B, Slawik B, Dixon B, French B, Routy B, Mavromatis B, Hayes-Lattin B, Barrow McCollough B, Fleissner B, Stith B, Wicher C, Schwartz C, Thomson C, Solorzano C, Granada C, Brown C, Hennessy C, Stratton C, Castellano C, Ang C, Mandapakala C, Wang C, Jani C, Su C, Misdary C, Chapman C, McNair C, Lemmon C, Geiger C, Friese C, Su C, McKeown C, Hoppenot C, Low C, Pillainayagam C, Ferrario C, Rock C, Gonzalez Gomez C, Masson C, Mundt D, Addison D, Flora D, Stover D, Kwon D, Hausrath D, Bowles D, Reuben D, Shafer D, Bitterman D, O' Sullivan D, Mahadevan D, Sohal D, Whaley D, Slosky D, Chism D, Hershman D, Doroshow D, Ravindranathan D, Farmakiotis D, Bhutani D, Vinh D, Freeman D, Johnson D, Hatton E, Van Allen E, Griffiths E, Davis E, Nakasone E, Loggers E, Robilotti E, Levine E, Cabebe E, Hsu E, Powell E, Nemecek E, Lau E, Durbin E, Bernicker E, Small E, Cook E, Gillaspie E, Reid E, Papadopoulos E, Tadesse E, Wehbe F, Lyman G, Schwartz G, Nagaraj G, Boland G, Demetri G, Batist G, Gantt Jr. G, Kloecker G, Shaw G, Riely G, Borno H, Saker H, Dzimitrowicz H, Nelson H, Khan H, Shaikh H, Polimera H, Chen J, Stratton J, Acoba J, Patel J, Connors J, Mather J, Henderson J, Dill J, Girard J, Warner J, Graber J, Papenburg J, Altman J, Hawley J, Clement J, Park J, Campian J, Philip J, Deeken J, Riess J, Rosenberg J, Loree J, Senefeld J, Kharofa J, Garcia J, Palmer J, Lewis J, Guido J, Fu J, Wu J, Jiang J, Gainor J, Klamerus J, Steve Lo K, Patel K, de Cardenas K, Vega-Luna K, Goldsmith K, Hansen K, Huber K, Stockerl-Goldstein K, Jeffords K, Hoskins K, Reynolds K, Cerrone K, Cortez K, Enriquez K, Rosen L, Lashley L, Pomerantz L, Smith L, Feldman L, Fecher L, Zubiri L, Liu L, Schapira L, Tachiki L, Weissmann L, Rosenstein L, Wang L, Tomasini M, Abidi M, Khan M, Shah M, Rovito M, Gatti-Mays M, Escobedo M, Alexander M, Bonnen M, Fiala M, Lewis M, Dailey M, Reeves M, Sueyoshi M, Portes M, Salazar M, Mulcahy M, Pasquinelli M, Lustberg M, Fiebach M, Luders M, Galsky M, Weiss M, Clark M, Smits M, Accordino M, Markham M, Gurley M, Thompson M, Bar M, Wagner M, Joyner M, Glover M, Wotman M, Braccioforte M, Marcum M, Seletyn M, Huynh-Le M, Santos Dutra M, Streckfuss M, Akhtari M, Gatson N, Bahadur N, Knox N, Edwin N, Pennell N, Bouganim N, Hafez N, Venepalli N, Williams N, Balanchivadze N, Ohri N, Butt O, Panagiotou O, Serrano O, Bohachek P, Egan P, Shah P, Caimi P, LoRusso P, Weinstein P, Yu P, Lammers P, Nuzzo P, Bindal P, Peddi P, Grover P, Zaman Q, Sica R, Rosovsky R, Elias R, Zon R, Gandhi R, Belenkaya R, Rice R, Buerki R, Herbst R, Mesa R, Lynch R, Nguyen R, Monahan R, Jhawar S, Alimohamed S, Jabbour S, Del Prete S, Mahmood S, Goel S, Revankar S, Matar S, Saif S, Mushtaq S, Wall S, Croessman S, Kligerman S, McWeeney S, Goyal S, Choi S, Brouha S, Taylor S, Vinayak S, Gadgeel S, Blau S, Hallmeyer S, Reid S, Williamson S, Fry S, May S, Berg S, Duda S, Greenland S, Murdock S, Subbiah S, Shah S, Shah S, Van Loon S, Ayre S, Owenby S, Rose S, Ahmad S, Zhang S, Latif T, Bekaii-Saab T, Cronin T, Nonato T, Rhodes T, Carducci T, Halfdanarson T, Sun T, Wise-Draper T, Masters T, Topaloglu U, Koshkin V, Mico V, Karivedu V, Walters W, Miller Jr. W, Li X, Rho Y, Xie Z, Sachs Z. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open 2021, 4: e2134330. PMID: 34767021, PMCID: PMC8590166, DOI: 10.1001/jamanetworkopen.2021.34330.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapySARS-CoV-2 infectionProstate cancerPropensity matchingDeprivation therapyCohort studyMalignant neoplasmsEastern Cooperative Oncology Group performance status scoreRole of ADTCOVID-19Androgen deprivation therapy useLarge ongoing clinical trialsPharmacologic androgen deprivation therapyCOVID-19 infection severityAndrogen-targeted therapiesBaseline steroid usePerformance status scorePrimary end pointSecond malignant neoplasmsPrimary malignant neoplasmsMonths of presentationBody mass indexOngoing clinical trialsCOVID-19 treatmentVanderbilt University Medical Center
2020
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, Consortium C, Abidi M, Acoba J, Agarwal N, Ahmad S, Ajmera A, Altman J, Angevine A, Azad N, Bar M, Bardia A, Barnholtz-Sloan J, Barrow B, Bashir B, Belenkaya R, Berg S, Bernicker E, Bestvina C, Bishnoi R, Boland G, Bonnen M, Bouchard G, Bowles D, Busser F, Cabal A, Caimi P, Carducci T, Casulo C, Chen J, Clement J, Chism D, Cook E, Curran C, Daher A, Dailey M, Dahiya S, Deeken J, Demetri G, DiLullo S, Duma N, Elias R, Faller B, Fecher L, Feldman L, Friese C, Fu P, Fu J, Futreal A, Gainor J, Garcia J, Gill D, Gillaspie E, Giordano A, Glace G, Grothey A, Gulati S, Gurley M, Halmos B, Herbst R, Hershman D, Hoskins K, Jain R, Jabbour S, Jha A, Johnson D, Joshi M, Kelleher K, Kharofa J, Khan H, Knoble J, Koshkin V, Kulkarni A, Lammers P, Leighton J, Lewis M, Li X, Li A, Lo K, Loaiza-Bonilla A, LoRusso P, Low C, Lustberg M, Mahadevan D, Mansoor A, Marcum M, Markham M, Marshall C, Mashru S, Matar S, McNair C, McWeeney S, Mehnert J, Menendez A, Menon H, Messmer M, Monahan R, Mushtaq S, Nagaraj G, Nagle S, Naidoo J, Nakayama J, Narayan V, Nelson H, Nemecek E, Nguyen R, Nuzzo P, Oberstein P, Olszewski A, Owenby S, Pasquinelli M, Philip J, Prabhakaran S, Puc M, Ramirez A, Rathmann J, Revankar S, Rho Y, Rhodes T, Rice R, Riely G, Riess J, Rink C, Robilotti E, Rosenstein L, Routy B, Rovito M, Saif M, Sanyal A, Schapira L, Schwartz C, Serrano O, Shah M, Shah C, Shaw G, Shergill A, Shouse G, Soares H, Solorzano C, Srivastava P, Stauffer K, Stover D, Stratton J, Stratton C, Subbiah V, Tamimi R, Tannir N, Topaloglu U, Van Allen E, Van Loon S, Vega-Luna K, Venepalli N, Verma A, Vikas P, Wall S, Weinstein P, Weiss M, Wise-Draper T, Wood W, Xu W, Yackzan S, Zacks R, Zhang T, Zimmer A, West J. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet 2020, 395: 1907-1918. PMID: 32473681, PMCID: PMC7255743, DOI: 10.1016/s0140-6736(20)31187-9.Peer-Reviewed Original ResearchConceptsLogistic regression analysisCause mortalityActive cancerCohort studySmoking statusRisk factorsCOVID-19Acute respiratory syndrome coronavirus 2 infectionEastern Cooperative Oncology Group performance statusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCOVID-19 disease courseBaseline clinical conditionsReceipt of azithromycinCoronavirus 2 infectionPotential prognostic variablesNumber of comorbiditiesActive anticancer treatmentCohort of patientsDays of diagnosisPotential prognostic factorsAmerican Cancer SocietyGeneral risk factorsRegression analysisSpecific cancer treatmentPhase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Strickler JH, LoRusso P, Salgia R, Kang YK, Yen C, Lin CC, Ansell P, Motwani M, Wong S, Yue H, Wang L, Reilly E, Afar D, Naumovski L, Ramanathan RK. Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics 2020, 19: 1210-1217. PMID: 32127466, DOI: 10.1158/1535-7163.mct-19-0529.Peer-Reviewed Original ResearchConceptsAdvanced solid tumorsSolid tumorsStable diseaseDose escalationCommon treatment-related adverse eventsAnti-c-Met antibodyTreatment-related adverse eventsDose-expansion phaseI Dose-EscalationAcceptable safety profileResponse Evaluation CriteriaDose-limiting toxicitySubset of patientsLinear pharmacokinetic profilePeak plasma concentrationAcute infusion reactionsHuman phase IDose cohortsDose expansionRECIST criteriaAdverse eventsEscalation cohortsInfusion reactionsObjective responsePartial responseDevelopment of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clinical Cancer Research 2020, 26: 1247-1257. PMID: 31527168, PMCID: PMC7528620, DOI: 10.1158/1078-0432.ccr-18-4071.Peer-Reviewed Original ResearchConceptsAdvanced malignanciesGrade treatment-related adverse eventsTreatment-related adverse eventsAdequate organ functionHigh interpatient variabilityFavorable PK profileOptimal dosing schemePrimary endpointAdverse eventsOral clearancePartial responseComplete responsePhase 1/2Terminal eliminationTolerability studyPatient populationPharmacodynamic profileInterpatient variabilityDosing schemesDistinct pharmacokineticsTherapeutic indexOrgan functionPK profilesExtraterminal (BET) inhibitorsTarget inhibitionA First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Varga A, Soria JC, Hollebecque A, LoRusso P, Bendell J, Huang SA, Wagle MC, Okrah K, Liu L, Murray E, Sanabria-Bohorquez SM, Tagen M, Dokainish H, Mueller L, Burris H. A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Clinical Cancer Research 2020, 26: 1229-1236. PMID: 31848189, DOI: 10.1158/1078-0432.ccr-19-2574.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDose-Response Relationship, DrugFatigueFemaleHumansMaleMAP Kinase Signaling SystemMaximum Tolerated DoseMiddle AgedMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NauseaNeoplasmsPatient SafetyProtein Kinase InhibitorsPyridonesPyrimidinesTissue DistributionVomitingConceptsBRAF-mutant colorectal cancerColorectal cancerAdverse eventsFDG-PETCommon drug-related adverse eventsSolid tumorsDrug-related adverse eventsPhase IPartial metabolic responseAcceptable safety profileAdvanced solid tumorsDose-proportional increaseGrade 3 rashMetastatic solid tumorsSerial tumor biopsiesSingle-agent activityBest overall responseHuman phase IMAPK pathway inhibitionMultiple tumor typesStable diseaseEscalation studyPartial responseOral inhibitorPharmacodynamic effects
2019
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, Lara PN, Chen X, Hu B, Freise KJ, Modi D, Sood A, Hutti JE, Wolff J, O'Neil BH. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clinical Cancer Research 2019, 25: 6309-6319. PMID: 31420359, DOI: 10.1158/1078-0432.ccr-19-0578.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsDose escalationSolid tumorsStable diseaseSafety profileProstate cancerCommon grade 3/4 treatment-emergent adverse eventsGrade 3/4 treatment-emergent adverse eventsHuman studiesMost common treatment-emergent adverse eventsCommon treatment-emergent adverse eventsMedian progression-free survivalTolerable safety profilePhase II doseAdvanced solid tumorsProgression-free survivalRefractory solid tumorsPreliminary antitumor activityMalignant solid tumorsAminotransferase elevationEvaluable patientsDose expansionExpansion cohortGastrointestinal bleedAdverse eventsPhase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clinical Cancer Research 2019, 25: 3220-3228. PMID: 30770348, PMCID: PMC7980952, DOI: 10.1158/1078-0432.ccr-18-2740.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorHumansImidazolesIndoleamine-Pyrrole 2,3,-DioxygenaseIndolesMagnetic Resonance ImagingMiddle AgedNeoplasm MetastasisNeoplasm StagingNeoplasmsTomography, X-Ray ComputedTreatment OutcomeConceptsPD-L1 inhibitorsT cellsPartial responseAdvanced cancerDay 1Dose levelsCommon treatment-related AEsDose-escalation stageTreatment-related AEsAdvanced solid tumorsEffector T cellsRegulatory T cellsLinear pharmacokinetic profileLocal tumor microenvironmentInvestigational small-molecule inhibitorExpansion patientsKynurenine accumulationComplete responseImmune suppressionIntravenous infusionAcceptable safetyTryptophan depletionNavoximodAtezolizumabPlasma Kyn
2018
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach J, Kapoun A, Xu L, Munster P. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Annals Of Oncology 2018, 29: 1561-1568. PMID: 29726923, DOI: 10.1093/annonc/mdy171.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalCohort StudiesDose-Response Relationship, DrugDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansMaleMaximum Tolerated DoseMiddle AgedNeoplasm Recurrence, LocalNeoplasmsPrognosisReceptor, Notch1Salvage TherapySurvival RateTissue DistributionConceptsNotch1 pathway activationPartial responseSolid tumorsPathway activationAdverse eventsCommon drug-related adverse eventsDrug-related adverse eventsDose-expansion studyGrade 3 diarrheaGrade 3 fatigueUnconfirmed partial responseRefractory solid tumorsProlonged SDsDisease stabilizationExpansion cohortMain toxicityRECIST 1.1Dose escalationEfficacy signalsClinical benefitPharmacodynamic effectsPreliminary efficacyAssessable subjectsImmunohistochemistry assaysNonlinear pharmacokinetics
2017
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R. A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Clinical Cancer Research 2017, 23: 4095-4106. PMID: 28264872, DOI: 10.1158/1078-0432.ccr-16-2796.Peer-Reviewed Original ResearchConceptsHigh-grade ovarian carcinomaObjective response rateInvestigator-assessed objective response rateOral rucaparibAdverse eventsCommon treatment-emergent adverse eventsTreatment-emergent adverse eventsAspartate transaminase elevationsAsthenia/fatigueProtocol-defined criteriaRECIST version 1.1Phase II doseAdvanced solid tumorsProgression-free intervalSmall molecule PARP inhibitorsClin Cancer ResManageable toxicityPrior regimensPrimary endpointTransaminase elevationPlatinum therapyMultiple dosesOvarian carcinomaAlanine transaminaseClinical activityA Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer
Schwartzberg LS, Yardley D, Elias A, Patel M, LoRusso P, Burris HA, Gucalp A, Peterson A, Blaney M, Steinberg J, Gibbons J, Traina TA. A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. Clinical Cancer Research 2017, 23: 4046-4054. PMID: 28280092, DOI: 10.1158/1078-0432.ccr-16-2339.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnastrozoleAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBenzamidesBreast NeoplasmsCytochrome P-450 CYP3ADose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsFemaleHumansMiddle AgedNeoplasm StagingNitrilesPhenylthiohydantoinPostmenopauseReceptors, EstrogenReceptors, ProgesteroneTriazolesConceptsEndocrine therapyEnzalutamide monotherapyBreast cancerEstrogen receptor-positive/progesterone receptor-positive breast cancerProgesterone receptor-positive breast cancerCytochrome P450 3A4 inducerRandomized phase II studyReceptor-positive breast cancerDose-expansion cohortsEffect of enzalutamidePhase II studyAdvanced breast cancerAndrogen receptor signalingBreast cancer modelClin Cancer ResDose modificationII studyPharmacokinetic interactionsPreclinical dataProstate cancerIb studyAdditional cohortMonotherapyCancer modelExemestane
2016
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Li C, Agarwal P, Gibiansky E, Jin J, Dent S, Gonçalves A, Nijem I, Strasak A, Harle-Yge M, Chernyukhin N, LoRusso P, Girish S. A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. Clinical Pharmacokinetics 2016, 56: 1069-1080. PMID: 27995530, DOI: 10.1007/s40262-016-0496-y.Peer-Reviewed Original ResearchConceptsNormal hepatic functionModerate hepatic impairmentHepatic impairmentMetastatic breast cancerHepatic functionTrastuzumab emtansineBreast cancerCycle 1Positive metastatic breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Phase I pharmacokinetic studyHuman epidermal growth factor receptorChild-Pugh criteriaMild hepatic impairmentT-DM1 3.6T-DM1 exposureGrowth factor receptor 2I pharmacokinetic studyFactor receptor 2Epidermal growth factor receptorGrowth factor receptorModerate cohortBaseline albuminT-DM1Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Nogova L, Sequist LV, Garcia J, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. Journal Of Clinical Oncology 2016, 35: 157-165. PMID: 27870574, PMCID: PMC6865065, DOI: 10.1200/jco.2016.67.2048.Peer-Reviewed Original ResearchConceptsFibroblast growth factor receptorGrowth factor receptorUrothelial cancerSafety profileAntitumor activitySolid tumorsGenetic alterationsKinase inhibitorsDose-expansion studyFGFR genetic alterationsMethods Adult patientsMTD/RP2DCommon adverse eventsManageable safety profilePhase II doseSimilar safety profileAdvanced solid tumorsContinuous scheduleDose-limiting toxicityFactor receptorCell lung cancerGrowth factor receptor 1Tyrosine kinase inhibitorsFibroblast growth factor receptor 1Factor receptor 1
2013
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
Naing A, LoRusso P, Fu S, Hong D, Chen H, Doyle L, Phan A, Habra M, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. British Journal Of Cancer 2013, 108: 826-830. PMID: 23412108, PMCID: PMC3590681, DOI: 10.1038/bjc.2013.46.Peer-Reviewed Original ResearchConceptsIGF-1R inhibitorsAdrenocortical carcinomaStable diseaseAggressive endocrine malignancyHuman IgG1 monoclonal antibodyProlonged stable diseaseMetastatic adrenocortical carcinomaGrowth factor receptor antibodyEffective systemic chemotherapyMTOR inhibitor temsirolimusIGF-1 receptorIgG1 monoclonal antibodyFrequent toxicitiesPrior therapySystemic chemotherapyMedian ageReceptor antibodiesPreclinical dataEndocrine malignancyMedian numberIGF-1RPatientsTemsirolimusCixutumumabGrade 1
2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
Macaulay V, Middleton M, Protheroe A, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay J, LoRusso P, Mery-Mignard D, Soria J. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Annals Of Oncology 2012, 24: 784-791. PMID: 23104723, PMCID: PMC3574548, DOI: 10.1093/annonc/mds511.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDiarrheaDocetaxelDoxorubicinErlotinib HydrochlorideFemaleGemcitabineHumansLeiomyosarcomaMaleMelanomaMiddle AgedQuinazolinesReceptor, IGF Type 1Skin NeoplasmsSoft Tissue NeoplasmsTaxoidsTreatment OutcomeConceptsAdvanced solid tumorsInsulin-like growth factor receptorType 1 insulin-like growth factor receptorGrowth factor receptorIGF-IISolid tumorsDisease controlCommon adverse eventsFactor receptorIGF-1R antibodyDurable disease controlCohort C2Adverse eventsPartial responseCohort BDocetaxel administrationSteroid premedicationControl ratePK interactionsGrade 3IGF-BP3Blood samplesCohort C1PatientsAVE1642
2011
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy
Garrett C, Siu L, El-Khoueiry A, Buter J, Rocha-Lima C, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten D. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. British Journal Of Cancer 2011, 105: 44-52. PMID: 21629245, PMCID: PMC3137402, DOI: 10.1038/bjc.2011.182.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanineAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabDrug Therapy, CombinationFemaleGastrointestinal NeoplasmsHumansMaleMiddle AgedNeoplasm Recurrence, LocalSalvage TherapySurvival RateTissue DistributionTreatment OutcomeTriazinesVascular Endothelial Growth Factor Receptor-2ConceptsAdvanced gastrointestinal malignanciesGastrointestinal malignanciesPhase I dose-escalation studyAdvanced metastatic colorectal cancerCommon treatment-related toxicitiesMedian progression-free survivalI dose-escalation studyRadiographic partial responseMetastatic colorectal cancerTreatment-related toxicityAcceptable toxicity profileDose-escalation studyPhase III studyProgression-free survivalOverall response rateK-ras mutationsAcneiform dermatitisPrior therapyAdverse eventsIII studyMedian durationMucosal inflammationPartial responseCombination chemotherapyColorectal cancerDose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Leal T, Remick S, Takimoto C, Ramanathan R, Davies A, Egorin M, Hamilton A, LoRusso P, Shibata S, Lenz H, Mier J, Sarantopoulos J, Mani S, Wright J, Ivy S, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemotherapy And Pharmacology 2011, 68: 1439-1447. PMID: 21479634, PMCID: PMC3481841, DOI: 10.1007/s00280-011-1637-5.Peer-Reviewed Original ResearchConceptsSevere renal dysfunctionNormal renal functionRenal dysfunctionAdult cancer patientsRenal functionDialysis patientsDose escalationCancer patientsPatient populationNational Cancer Institute Organ Dysfunction Working Group StudyDose of bortezomibImpaired renal functionGeneral patient populationIntravenous bortezomibRenal impairmentCreatinine clearanceModerate dysfunctionMild dysfunctionSevere dysfunctionDose reductionPharmacologic dataPatientsDay 1DysfunctionBortezomib